Art Painter / Shutterstock.com
1 April 2016Africa
GSK to widen access to medicines in world’s poorest countries
Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Africa
12 February 2016 GSK has been fined more than £37 million by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat.
Big Pharma
17 March 2016 Pharmaceutical company GSK has announced to shareholders that its chief executive Sir Andrew Witty will be retiring from his role in 2017.
Editor's picks
Editor's picks
Africa
12 February 2016 GSK has been fined more than £37 million by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat.
Big Pharma
17 March 2016 Pharmaceutical company GSK has announced to shareholders that its chief executive Sir Andrew Witty will be retiring from his role in 2017.
Africa
12 February 2016 GSK has been fined more than £37 million by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat.
Big Pharma
17 March 2016 Pharmaceutical company GSK has announced to shareholders that its chief executive Sir Andrew Witty will be retiring from his role in 2017.